U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07439029) titled 'YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases' on Feb. 08.
Brief Summary: This exploratory, single-arm, open-label study will evaluate the safety and preliminary efficacy of YTS109 cell therapy in pediatric patients with relapsed/refractory autoimmune diseases, including systemic lupus erythematosus, diffuse systemic sclerosis, idiopathic inflammatory myopathies, and Sjogren's syndrome, as well as other eligible autoimmune diseases defined by the protocol eligibility criteria. Approximately 12 patients aged 5 to <18 years will be enrolled at Children's Hospital of Fudan University and will receive a single intravenous ...